Merck, Schering-Plough Dodge Vytorin Enforcement Bullet
This article was originally published in The Pink Sheet Daily
Executive SummaryIn settlement with state attorneys general, the companies agree to pay $5.4 million to cover investigative costs and recommit to routine oversight policies.
You may also be interested in...
Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.